Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
An antibody designed to neutralize proplatelet basic protein (PPBP), also known as CXCL7. PPBP is a member of the CXC chemokine family primarily derived from platelets and, as recently identified, adipose tissue macrophages in the context of chronic inflammation. In preclinical models of psoriasis-associated atherosclerosis, PPBP has been shown to induce mitochondrial dysfunction in aortic endothelial cells via the ZNG1F pathway. Treatment with anti-PPBP antibodies has demonstrated efficacy in reducing atherosclerotic plaque formation in ApoE-deficient mice, suggesting that targeting the PPBP-CXCL7 axis may provide a therapeutic strategy for mitigating cardiovascular risk in patients with systemic inflammatory conditions like psoriasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-pro-platelet basic protein antibody.